Syndax Prices Public Offering of Common Stock
May 24, 2017 19:22 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at...
Syndax Announces Proposed Public Offering of Common Stock
May 23, 2017 16:48 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of...
Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
May 17, 2017 17:07 ET
|
Syndax Pharmaceuticals, Inc.
-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- -ENCORE 601 now enrolling expanded cohorts...
Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
May 16, 2017 17:26 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference
May 15, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer...
Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update
May 08, 2017 16:05 ET
|
Syndax Pharmaceuticals, Inc.
Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter Company to host conference call today at 4:30...
Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
May 01, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the...
Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer
April 27, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration...
Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
April 20, 2017 16:05 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and...
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
April 04, 2017 07:00 ET
|
Syndax Pharmaceuticals, Inc.
WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...